AA
COGT icon

ALPS Advisors’s Cogent Biosciences COGT Stock Holding History

ALPS Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-87,463
Closed -$945K – 1003
2024
Q3 		$945K Buy
87,463
+12,865
+17% +$125K 0.01% 508
2024
Q2 		$629K Buy
+74,598
New +$566K ﹤0.01% 547
2023
Q2 		– Sell
-46,045
Closed -$497K – 1010
2023
Q1 		$497K Sell
46,045
-1,335
-3% -$17.1K ﹤0.01% 593
2022
Q4 		$548K Buy
47,380
+11,479
+32% +$142K ﹤0.01% 574
2022
Q3 		$536K Buy
35,901
+8,720
+32% +$120K 0.01% 578
2022
Q2 		$245K Sell
27,181
-13,779
-34% -$94K ﹤0.01% 951
2022
Q1 		$307K Sell
40,960
-5,156
-11% -$35.9K ﹤0.01% 763
2021
Q4 		$396K Buy
+46,116
New +$401K ﹤0.01% 671

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

ALPS Advisors's COGT Position: Q4 2024 in Review

ALPS Advisors sold out of Cogent Biosciences (COGT) in Q4 2024, closing a stake of 87,463 shares — an estimated $945K sold.

ALPS Advisors first reported a position in COGT in Q4 2021 and held it in 8 quarters. The position peaked at $945K in Q3 2024. 176 funds tracked by Wall St. Rank hold COGT as of Q4 2024.

  • ALPS Advisors reported no remaining Cogent Biosciences position as of Q4 2024 after selling out during the quarter.
  • ALPS Advisors sold 87,463 Cogent Biosciences shares in Q4 2024, an estimated $945K.
  • ALPS Advisors first reported a position in Cogent Biosciences in Q4 2021 and held it in 8 quarters.
  • ALPS Advisors's Cogent Biosciences position peaked at $945K in Q3 2024.
  • 176 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2024.

Based on ALPS Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.